|
|
| Line 872: |
Line 872: |
| **Citation: Thomson K, Karouta C, Ashby R. Administration of Nicotine Can Inhibit Myopic Growth in Animal Models. Invest Ophthalmol Vis Sci. 2024 Sep 3;65(11):29. doi: 10.1167/iovs.65.11.29. PMID: 39292451; PMCID: PMC11412605. | | **Citation: Thomson K, Karouta C, Ashby R. Administration of Nicotine Can Inhibit Myopic Growth in Animal Models. Invest Ophthalmol Vis Sci. 2024 Sep 3;65(11):29. doi: 10.1167/iovs.65.11.29. PMID: 39292451; PMCID: PMC11412605. |
| ***Acknowledgement: Funded by ANU Connect Ventures through a Discovery Translation Fund grant (Project ID: DTF311). | | ***Acknowledgement: Funded by ANU Connect Ventures through a Discovery Translation Fund grant (Project ID: DTF311). |
| <br>
| |
|
| |
| ='''Huntington’s Disease'''=
| |
|
| |
| ===2005: [https://pubmed.ncbi.nlm.nih.gov/16140176/ Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats]===
| |
| *These results clearly showed neuroprotective effect of nicotine in experimental model of HD. The clinical relevance of these findings in HD patients remains unclear and warrants further studies.
| |
| *In conclusion, nicotine significantly and dose-dependently attenuated 3-NP-induced striatal lesions and behavioral deficits in rats. The protective effect of nicotine may be attributed to its ability of restoring striatal DA levels in 3-NP intoxicated rats.
| |
| *[https://sci-hub.se/10.1016/j.brainresbull.2005.06.024 PDF Version]
| |
| **Citation: Tariq M, Khan HA, Elfaki I, Al Deeb S, Al Moutaery K. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats. Brain Res Bull. 2005 Sep 30;67(1-2):161-8. doi: 10.1016/j.brainresbull.2005.06.024. PMID: 16140176.
| |
| <br> | | <br> |
|
| |
|